Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Magnetic resonance imaging
Clinical narrative: it recurred as a severe headache; mild headache/lingering mild headache; This is a spontaneous report from a sponsored program support via a contactable consumer (patient) reported for herself. A 78-year-old female patient received second dose of BNT162B2 (COVID-19 VACCINE, Formulation: Solution for injection, Lot number: unknown; Expiration date: unknown) via an unspecified route of administration, administered at an unspecified anatomical location on 13Feb2021 (age at vaccination was 78 years) as 2ND DOSE, SINGLE for COVID-19 immunization. The patient's medical history was not reported. Concomitant medications included prednisone acetate. The patient previously took first dose of BNT162B2 (COVID-19 VACCINE, Formulation: Solution for injection, Lot number: unknown; Expiration date: unknown) via an unspecified route of administration, administered at an unspecified anatomical location on an unknown date (age at vaccination was unknown) as 1ST DOSE, SINGLE for COVID-19 immunization. The caller declined transfer as she had already given all of her information. She was open to being followed-up with by the safety department and indicated that email was the fastest way. The caller was a consumer who completed her COVID-19 vaccine series on 13Feb2021.  On 16Feb2021 and 17Feb2021, she woke up with a mild headache, which resolved. On 19Feb2021, it recurred as a severe headache, and caller stated she was worried she had a brain tumor.  She went for an MRI, which came back normal.  Her headaches persisted, and her provider prescribed Prednisone 20mg for 5 days, which she thought cured her headache. The headaches had persisted, but she reported they were "minor" and "annoying". Typically her headaches were present in the morning and resolved throughout the day.  Her headache, today, persisted which prompted the call to report. She asked whether they had reports of this happening to anyone else. She received a response stating that headaches are commonly reported AEs, which are more common after the second dose. Provided usual duration from attached "CONS -How long side effects last final (v2.0)". Directed caller back to HCP for treatment advice,  if she were to experience additional symptoms, or if she forgot anything in her report. The caller called because she took the vaccine in February and has had a lingering mild headache since then. She wanted to know if it was because of the vaccine because she never had headaches. The outcome of event mild headache/lingering mild headache (first occurrence) was recovered on an unknown date in 2021. The outcome of the event it recurred as a severe headache (second occurrence) was unknown. Follow-up #01 (14May2021): New information received from support via a contactable consumer (patient) included: Details regarding reporter's contact information availability and medical questions addressed by the program forwarded/referred to Medical Information. Follow-up #02 (14May2021): New information received from support via a contactable consumer (patient) included: No new information and adverse event added. Follow up attempts are completed. No further information is expected.